BioCentury | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

...fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Sutent, sunitinib (SU11248) Tagrisso (Brand), AZD9291, osimertinib (Generic), Tagrisso (Other) Tasigna, nilotinib (AMN107) Vidaza...
BioCentury | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

...NYSE:NVS; SIX:NOVN) for myelofibrosis; Gilotrif afatinib from Boehringer Ingelheim GmbH (Ingelheim, Germany) for NSCLC; Tasigna nilotinib...
BioCentury | Jul 20, 2018
Company News

Novartis halts price increases, reports 2Q earnings

...Basel, Switzerland Business: Pharmaceuticals Jaime De Leon Gilenya, Imusera, fingolimod (FTY720, TDI-132) Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Tasigna, nilotinib (AMN107) Novartis...
BioCentury | Jul 18, 2018
Company News

Novartis halts price increases, reports 2Q earnings

...figures provided by FactSet. Jaime De Leon Gilenya, Imusera, fingolimod (FTY720, TDI-132) Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Tasigna, nilotinib (AMN107) Novartis...
BioCentury | May 18, 2018
Company News

FDA names, shames ‘anticompetitive’ drug companies

...involved drugs that did not have an ETASU -- Afinitor everolimus, Exjade deferasirox and Tasigna nilotinib...
...ICL670 (Compound #), deferasirox (Informal), Exjade (Other) Imnovid, Pomalyst, pomalidomide (CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid...
BioCentury | May 17, 2018
Politics & Policy

FDA names, shames ‘anticompetitive’ drug companies

...involved drugs that did not have an ETASU -- Afinitor everolimus, Exjade deferasirox and Tasigna nilotinib...
...ICL670 (Compound #), deferasirox (Informal), Exjade (Other) Imnovid, Pomalyst, pomalidomide (CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid...
BioCentury | Jan 18, 2018
Emerging Company Profile

Computing brain entry

...AG’s leukemia drug Tasigna nilotinib modestly improved motor symptoms and cognitive performance in PD patients. Tasigna...
...in the indication. Kim noted 1ST-102 has a hundred- to thousand-fold better BBB penetration than Tasigna...
BioCentury | Jan 3, 2018
Clinical News

Novartis' Tasigna gets treatment-free remission FDA label expansion

...FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some...
...to treat Philadelphia chromosome-positive (Ph+) CML in chronic phase. At 96 weeks after stopping treatment, Tasigna...
...CML in chronic phase. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tasigna nilotinib Business: Cancer Allison Johnson nilotinib Tasigna Novartis...
BioCentury | Dec 26, 2017
Company News

FDA approves treatment-free remission label update for Tasigna

...FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some...
...to treat Philadelphia chromosome-positive (Ph+) CML in chronic phase. At 96 weeks after stopping treatment, Tasigna...
...Tasigna as first- and second-line treatment for pediatric patients with Ph+ CML in chronic phase. Allison Johnson nilotinib Tasigna Novartis...
BioCentury | Jun 16, 2017
Clinical News

Novartis' Tasigna gets EU label update to include treatment-free remission data

...Novartis AG (NYSE:NVS; SIX:NOVN) said the European Commission approved a label expansion for Tasigna nilotinib to...
...Tasigna is a BCR-ABL tyrosine kinase (BCR-ABL) inhibitor. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tasigna...
...tyrosine kinase (BCR-ABL) inhibitor. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tasigna nilotinib Business: Cancer Alex Himes nilotinib Tasigna Novartis...
Items per page:
1 - 10 of 191